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1. Introduction
Behçet’s disease (BD) is a multisystem inflammatory disease with unknown etiology [1]. It 
may affect vascular, gastrointestinal, neurologic, articular, pulmonary, cardiac, and  urogenital 
systems [1, 2].
2. History
The disease was first described by a Turkish dermatologist, Hulusi Behçet, in 1937 as a 
 triple symptom complex; aphthous stomatitis, genital ulcers, and relapsing uveitis [2]. 
Hulusi Behçet was born in 1889 in Istanbul/Turkey. In 1910, he became a medical doctor, 
and in 1914, he received a dermatologist title. In 1933, he became a professor of  dermatology 
and venereal diseases. Hulusi Behçet is the first academician with a titled professor in the 
 history of Turkish academy. Hulusi Behçet observed aphthous symptoms in the mouth and 
 genital area and several findings in the eye in his three patients whom he followed 21, 7 and 
3 years. He believed that this was a new disease. In 1937, he reported his observations in 
“DermatologischeWochenschrift” and then he presented his patients in a dermatology meeting 
in Paris. In later times, same cases were reported from various regions of the world. In 1947, 
the new disease was named as “Morbus Behçet” in International Congress of Geneva [3].
3. Epidemiology
BD has a worldwide distribution. But it is commonly observed in the Silk Road countries 
between the Mediterranean Sea, including such countries Spain, Portugal, Turkey, Iran, and 
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Far East countries like China and Japan [4, 5]. The disease is most common in Turkey with the 
prevalence of 20-602 per 100.000 [6, 7]. It develops at any age, but it most appears between 
the second and fourth decade of life [8]. BD patients with early onset may have the more 
severe disease [9]. BD is uncommon in children. Patients with initial symptoms at age 16 years 
or younger are classified as juvenile-onset BD. The prevalence of juvenile BD is unknown. But 
in few series, it is reported between 3, 3 and 26% of BD patients were before age of 16 years 
[10]. BD affects the both gender equally [11]. The disease is more severe among male patients, 
and vascular disease is the major risk factor of death in male patients. It is shown that vascular 
disease, folliculitis, papulopustular skin lesions, positive pathergy test, and ocular disease are 
more common in men while erythema nodosum, genital ulcers, and joint involvement are 
more common among women [12, 13].
4. Etiology
Although several immunological abnormalities have been demonstrated, the real etiologic 
mechanism of the disease is unclear.
4.1. Infectious agents
The most probablehypothesis is that in genetically predisposed individuals some infectious 
agents such as Herpes simplex virus (HSV)-1, Streptococcus sangiuinis (S. sanguinis) or some 
autoantigens such as heat shock proteins (HSP) trigger the autoinflammatory reactions [1]. 
BD has aspects of both autoimmune disease and auto inflammatory disease. The autoim-
munity indicators are the effectiveness of classical immunosuppressives such as azathioprine 
and cyclosporine, and the suggested role of the candidate autoantigen, human heat-shock 
protein 60 (HSP60). Also, the lack of significant high-titer autoantibodies or antigen-specific 
T-cells, strong involvement of major histocompatibility complex (MHC) class I molecules, 
clinical episodes of unprovoked recurrent inflammation, mainly caused by neutrophils, and 
the therapeutic effectiveness of colchicine, are signs of autoinflammation [14].
Infection agents have an important role in the pathogenesis of BD. Several investigations have 
shown the association between HSV and BD. But, in some studies, this association could not 
detected [1, 15, 16]. Therefore, the role of HSV at the etiopathogenesis of BD is not clear.
Several potential bacteria have been investigated but the most commonly implicated micro-
organism is S. sanguinus [17]. It was found that Bes-1 gene and HSP-65 derived from oral 
S. sanguinis, are supposed to play important roles as an extrinsic factor in BD pathogenesis. 
The peptides of the Bes-1 gene are highly homologous with the retinal protein Brn3b, and 
moreover, the Bes-1 peptides were homologous with HSP-65 derived from microorganisms 
in association with the counterpart human HSP-60, which appeared reactively in the BD 
patients. Some homologous peptides of HSP-65 were found to reduce IL-8, IL-12, and TNF-
alpha in active BD patients [18]. Also, it is shown that S. sanguinis antigens increase IFN-γ and 
IL-6 secretion from the peripheral blood cell T cell of BD patients [19].
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From another report, it was detected that Streptococcus mutans (S. mutans) colonization rate 
was significantly higher in BD. S. mutans presence in saliva was associated with oral ulcers, 
and it was associated with severe disease course than milder disease [20].
Heat shock protein (HSP) functions as an intracellular chaperonin of other proteins and sig-
nificant sequence homology is found between mammalian HSP and microbial HSP HSP60/65 
was thought to be a major cause of the skewed immune responses in patients with BD because 
of the molecular mimicry between human HSP and microbial HSP. HSP60 regulates Th1 cell 
differentiation through multiple immunologic pathways [21].
Gut microbiota compositional alteration may have an association with immune dysfunction 
in patients with BD. Direct comparison of the relative abundance of bacterial taxa demon-
strated that the genera Bifidobacterium and Eggerthella increased significantly and the genera 
Megamonas and Prevotella decreased significantly in BD patients compared with normal indi-
viduals. The authors suggested that the compositional changes of gut microbes may be one 
type of dysbiosis (unfavorable microbiota alteration) in patients with BD. The dysbiosis may 
have an association with the pathophysiology of BD [22].
4.2. Genetic factors
Genetic factors play important roles in the pathogenesis of BD. Multiple studies have demon-
strated that BD is strongly associated with the presence of human leukocyte antigen (HLA)-B5 
and its split antigen HLA-B51 [11, 23]. The association with HLA-B5 was first described by 
Ohno et al. in 1973. Several studies confirmed the HLA-B51 association with BD and HLA-B51 
is the strongest known genetic factor for BD [1]. The MHC region on chromosome 6p21 con-
tains HLA and other essential genes in the immune response [14]. A meta-analysis based on 
72 studies in 74 study populations revealed the moderate association of HLA-B5/-B*51 with 
male gender, the high prevalence of eye involvement, skin involvement, and genital ulcers, 
and low prevalence of gastrointestinal involvement [24]. Some of the other susceptible genes 
associated with BD are IL10, IL23R-IL12RB2, STAT4, TNFAIP3, CCR1-CCR3, KLRC4, FUT2, 
IL12A, IL23R, TLR4, MEFV, and NOD2. The genes identified are involved in both innate and 
adaptive immunity and support the idea that polarization in Th1/Th17 pathway plays a critical 
role in BD pathogenesis [14].
5. Clinical manifestations
5.1. Mucocutaneous findings
5.1.1. Oral aphthosis (ulceration)
Oral ulceration is the most detected symptom that seen over 97% of the patients. It is a pain-
ful, recurrent, round, and oval ulceration with well-defined borders and central yellowish 
pseudomembrane. An erythematous halo surrounds the ulcers. The most common sites are 
mucous membranes of the lips, buccal mucosa, tongue, and soft palate. They can be  classified 
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as minor, major or herpetiform on the basis of ulcer size and number. Oral ulcer often 
resolves spontaneously within 1–4 weeks. Local trauma can trigger new oral ulceration. At 
the  differential diagnosis of oral ulcers herpes simplex, erythema multiforme, fixed drug 
 eruption, MAGIC syndrome, Reiter’s syndrome, and Sweet’s syndrome, anemia due to a 
deficiency of iron, vitamin B12 or folic acid, inflammatory bowel diseases, and systemic lupus 
erythematosus must consider [1, 25, 26].
5.1.2. Genital ulcers
Genital ulcers can be seen 60–89% of the patients. Genital ulcers are similar in appearance 
to oral ulcers. The scrotum is the most frequently involved site in males. Ulcers can also 
be observed on the shaft and glans penis. In females, the ulcers most commonly occur on the 
labia but the vaginal mucosa and rarely the cervix can also be affected. Vaginal ulcers often 
cause a discharge. GU may occur in both sexes in the groin, perineal and perianal area. They 
usually heal within 10–30 days and deep ulcers may lead scarring. Genital herpes simplex 
infection, erythema multiforme, fixed drug eruption, sexually transmitted diseases such as 
syphilis, chancroid, lymphogranuloma Venere um and HIV infection should be considered in 
differential diagnosis [1, 25, 26].
5.1.3. Erythema nodosum like lesions
Erythema nodosum like lesions is mostly seen in females. They are characterized by painful 
multiple subcutaneous nodules that vary in size and color. They are frequently seen at the 
lower extremities but they can also be localized to the face, neck, forearms, and buttock. The 
lesions resolve spontaneously within 2–3 weeks. The histopathological features of erythema 
nodosum-like lesions are characterized by the presence of vasculitis or vascular reaction; 
different from erythema nodosum secondary to other systemic causes. The presence of the 
erythema nodosum like lesion may be an indicator of the mildness of Behçet’s disease; 
and the presence of histopathological evidence of severe vasculitis, especially phlebitis, in 
erythema nodosum-like lesions may be an indicator of the involvement of the gastrointestinal 
tract in Behçet’s disease [1, 26, 27].
5.1.4. Papulopustularlesions (PPL)
PPL are cutaneous, sterile, folliculitis – or acne-like lesions on an erythematous base which 
appear as a papule and in the course of 24–48 h become a pustule. Trunk, buttocks, and the 
lower limbs are the most common localizations. Differential diagnosis of PPL is difficult from 
acne vulgaris. In a recent study, it is suggested that in BD patients the inflammatory lesions 
located on the face were less than those in the acne vulgaris. Inflammatory lesions such as fol-
liculitis on the legs were only seen, in the BD group. The papulopustular lesions of BD could 
not be distinguished from AV by histology [1, 25, 28].
5.1.5. Superficial thrombophlebitis
Superficial thrombophlebitis is the most frequent type of venous involvement. The patients 
usually present with erythematous, tender, subcutaneous nodules arranged in a linear  fashion. 
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The small vein can be palpated as a string-like hardening of the subcutaneous tissue with 
reddening of the overlying skin. It is more common in males and frequently confused with 
erythema nodosum like lesions. Superficial thrombophlebitis is often associated with other 
forms of vascular disease in BD [1, 25].
5.1.6. Other cutaneous lesions
Extragenital ulcerations clinically resemble aphthous lesions of the disease. They are recur-
rent and usually heal with scarring. The lesions have been reported on various locations such 
as the legs, axillae, breast, neck, interdigital skin of the foot, inguinal region, and neck.
Sweet syndrome like lesions are characterized by painful erythematous plaques and nod-
ules which usually localize to face, neck, and extremities. Other cutaneous vasculitic lesions 
include pyodermagangrenosum-like, erythema multiforme-like lesions, palpable purpura, 
subungual infarctions, hemorrhagic bullae, furuncles, and abscesses [1, 3, 25].
5.1.7. Skin pathergy test
Pathergy phenomenon is defined as a state of altered tissue reactivity that occurs in response 
to minor trauma. A papule or a sterile pustule occurs 24–48 h after an intradermal injection 
of the skin with a 20-gauge needle. The positivity rate of pathergy test in BD was found to 
vary from country to country. It is most prevalent around the silk route, which extends from 
the Far East to the Mediterranean Basin. Other diseases that can be seen positive pathergy 
test are; pyodermagangrenosum, interferon alpha-treated chronic myeloid leukemia patients, 
Sweet’s syndrome, eosinophilic pustular folliculitis, inflammatory bowel disease and healthy 
individuals [26, 29].
5.2. Ocular manifestations
Ocular involvement is one of the most disabling complications of BD, causing loss of vision 
that may progress to blindness if left untreated. The typical form of ocular involvement is a 
relapsing and remitting panuveitis and retinal vasculitis. Uveitis occurs in approximately two-
thirds of BD patients. A single attack will usually heal spontaneously without a sequel. But 
destructive and recurrent attacks, especially with the posterior segment and retina involve-
ment, may cause irreversible ocular structural changes and permanent damage in the sensory 
retina, resulting in loss of vision [30, 31].
5.3. Vascular involvement
Vascular involvement in BD includes venous thrombosis, arterial occlusion, and pulmonary 
artery and aortic aneurysm formation [32]. Lower extremity deep venous thrombosis is the 
most common form of vascular involvement in BD [9]. Venous thrombosis may occur at any 
site of the body and any size of vessels may be affected [26]. Inferior vena cava, superior 
vena cava, and pulmonary artery are the other common involved vessels. Pulmonary artery 
involvement, the most common form of arterial involvement, manifests as aneurysms and “in 
situ” thrombosis. Pulmonary artery involvement and Budd-Chiari syndrome are the leading 
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causes of increased mortality. In a vascular cluster, typically, several types of venous or arte-
rial vascular involvement may accumulate in the same individual. Vascular involvement is 
more common and more severe among males [33].
5.4. Gastrointestinal involvement
Intestinal BD is characterized by ulcers on the gastrointestinal tract, usually at the ileocecal 
region. Patients can present with abdominal pain, diarrhea, constipation or acute abdomen 
due to perforation of an ulcer. To distinguish clinical symptoms of intestinal BD from inflam-
matory bowel disease may be difficult. Some colonoscopy and histopathological findings may 
help for differentiating the two disease [9, 26].
5.5. Neurologic involvement
Neurobehcet disease is a rare complication of BD. But it is an important cause of  morbidity 
and mortality in BD. Little is known about this neuro-Behçet because there are no confirmed 
diagnostic criteria, and all the studies have a small number of patients. The prevalence 
reported normally ranges between 5 and 15% and it is more frequent amongst men between 
20 and 40 years old. The typical presentations include focal parenchymal lesions, vascular 
thrombosis, arterial vasculitis, and aseptic meningoencephalitis [34].
5.6. Joint involvement
Joint manifestations are common in Behçet’s disease. Most patients suffer from a nonerosive, 
nondeforming oligoarthritis typically involving the knees, ankles, and wrists [35].
6. Diagnosis
There is not a universally accepted pathognomonic test for diagnosis of BD. The diagnose is 
primarily based on clinical criteria and exclusion of alternative diagnosis [1]. Various  criteria 
have been used. The mostly used one is International Study Group for Behçet’s Disease 
 criteria (ISG criteria) which formulated at 1990. According to ISG criteria, the presence of oral 
aphthosis was mandatory. Two of the following symptoms were required for the diagnosis 
of BD: Genital aphthosis, skin manifestations, ocular lesions, and positive pathergy reaction 
[36]. Later in 2006, a new set was proposed by the International Team for the Revision of the 
International Criteria for Behçet’s Disease (ITR-ICBD). According to ITR-ICBD, oral aphthosis, 
skin manifestations, vascular manifestations, and positive pathergy reaction score one point 
each. Genital ulcers and ocular manifestations get two points each. The diagnosis of BD 
is made when three or more points are collected [37]. Then at 2013, the new criteria were 
revised under the name International Criteria for Behçet’s disease (ICBD). In this criteria oral 
ulcer, genital ulcer, and ocular manifestations get each two points; skin lesions, neurological 
 manifestations, vascular manifestations, and positive pathergy test get each one point. For the 
diagnosis, four points are required [38].
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7. Prognosis
BD has a chronic course with unpredictable remissions and exacerbations. The diagnosis is 
difficult in many patients because there is not a universally accepted diagnostic criteria and 
the clinical symptoms may be seen in many other diseases. In a study from Germany, it was 
shown that because of the ethnicity, in Turkish patients, the diagnosis of BD is earlier than 
German patients. Because in German patients the diagnosis was later and more difficult than 
Turkish patients, some of the patients might be followed with the wrong diagnosis for long 
times. It is mentioned that the diagnosis is more difficult in non-endemic areas [39]. But rec-
ognizing the disease may permit early diagnosis and treatment. An oral ulcer is the most com-
monly seen clinical symptom followed by a genital ulcer, PPL, erythema nodosum like lesions 
and articular and ocular lesions. These clinical symptoms lead to pain and loss of function. On 
the other hand pulmonary especially large vessel involvement, neurological involvement, and 
bowel perforation are causes of mortality [1]. It is shown that male sex, arterial involvement, 
and a high number of BD flares were independently associated with the risk of mortality [40].
8. Conclusion
BD is a chronic inflammatory multisystem disease that affects any size of the vessels. The 
 etiology is not clear yet. However, infectious and genetic factors are thought to act roles in 
the etiopathogenesis. There is no specific serological marker and the diagnosis of the disease 
depends on clinical criteria only. Moreover, the clinical symptoms of the disease may be seen 
in many diseases. So, knowing the findings, diagnostic criteria, prognosis, and complications 
of the disease provides the early diagnosis of the BD that is very important for the treatment 
of the disease, which has risks of mortality and morbidity. So, in this book, epidemiology, etio-
pathogenesis, cutaneous, and systemic findings and treatment of BD will be reviewed in detail.
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